Author:
Zachmann Milo,Eiholzer Urs,Muritano Mariarosaria,Werder Edmond A.,Manella Brigitte
Abstract
Abstract
22 Boys with pubertal gynaecomastia (age 15.9+/−1.9 years) were treated with testolactone (450 mg daily by mouth) for 2 to 6 months without side-effects. The mean breast gland diameter regressed from 4.4 to 3.3, 3.2 cm, and 1.7 cm at 2,4, and 6 months, while pubic hair and testicular volume progressed normally. Plasma androstenedione increased from 5.4 to 73.1 nmol/l. Testosterone, DHEA, and oestrone increased less, and oestradiol remained unchanged. Androgen/oestrogen ratios increased (most marked change: androstenedione/oestrone from 15 to 140). LH (basal and maximum after LHRH) did not change, but FSH increased somewhat (basal 133 to 173, maximum 225 to 269 μg/l). Prolactin remained unchanged. It is concluded that testolactone, an inhibitor of steroid aromatization, is an effective and safe medical treatment for pubertal gynaecomastia.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Testolactone: The Rise and Fall of a Drug;Drugs and Drug Candidates;2023-02-04
2. Gynecomastia: A systematic review of pharmacological treatments;Frontiers in Pediatrics;2022-11-01
3. Gynecomastia;The Breast;2018
4. Gynecomastia;Endocrine Surgery in Children;2017-08-02
5. S1 guidelines: Gynecomastia in adults;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2017-04